

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button							Add
NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Ts

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

1	3M™, Tegaderm Family of Transparent Dressings for Chronic Wounds, pp. 1-8, copyright (2002). NPL-002	<input type="checkbox"/>
2	Aeros, "Moblivac," "Introducing the 'off the wall' vacuum system," Aeros Instruments, Life Support Nursing, 3(1):34-37, Berlin Publishing Ltd. (January - February 1980). NPL-007	<input type="checkbox"/>
3	ALEXANDER, J.W., et al., "Clinical evaluation of epigard, a new synthetic substitute for homograft and heterograft skin," J. of Trauma, 13(4):374-383, (April 1973). NPL-010	<input type="checkbox"/>
4	ALPER, J.C., et al., "Moist wound healing under a vapor permeable membrane", J. Am. Acad. Dermatol., 8 (3):347-353, (March 1983). NPL-012	<input type="checkbox"/>
5	ANON., "Standard Test Methods for Water Vapor Transmission of Materials," ASTM International, Designation: E 96/E 96M - 05, 11 sheets, (Exhibit D-184) (June 2005). NPL-017	<input type="checkbox"/>
6	ARGENTA, P.A., et al., "Vacuum-assisted closure in the treatment of complex gynecologic wound failures," Obstet. Gynecol., 99(3):497-501, (9 sheets) (March 2002). NPL-018	<input type="checkbox"/>
7	Author unknown, p.42, "The Not-So-Bald-Truth" (September 1992). NPL-022	<input type="checkbox"/>
8	AUSTAD, E.D., et al., "Tissue expansion: dividend or loan?" Plast. Reconstr. Surg.,78(1):63-67 (July 1986). NPL-023	<input type="checkbox"/>
9	AZAD, S., et al., "Topical negative pressure may help chronic wound healing," B M J., 324:1100 (1 sheet) (May 4, 2002). NPL-026	<input type="checkbox"/>
10	BALLARD, K., et al., "Developments in wound care for difficult to manage wounds," Br. J. Nurs., 9(7) 405-8,410,412 (April 13-26, 2000). NPL-030	<input type="checkbox"/>
11	BALLARD, K., et al., "Vacuum-assisted closure," Nurs. Times, 97(35):51-2 (5 sheets) August 30 - September 5, 2001. NPL-031	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

12	BALLARD, K., et al., "Use of vacuum-assisted closure therapy following foot amputation," Br. J. Nurs., 10(15 Supplement) S6, 8, 11-12 (August 2001). NPL-032	<input type="checkbox"/>
13	BANWELL, P.E., "Topical negative pressure therapy in wound care," J. Wound Care, 8(2):79-84 (February 1999). NPL-034	<input type="checkbox"/>
14	BARTELS, C.G., et al., "The vacuum sealing technique. A new approach to cover soft tissue defects, used after the resection of a leiomyosarcoma", (English abstract on 2nd page and 1 page printout from PubMed); Hautarzt, 52 (7):653-7 (July 2001). NPL-039	<input type="checkbox"/>
15	BAUER, P., et al., "Possibilities of preliminary treatment of infected soft tissue defects by vacuum sealing and PVA foam", (English abstract on first page and 1 sheet PubMed abstract), Handchir. Mikrochir. Plast. Chir., 30(1):20-3 (January 1998). NPL-040	<input type="checkbox"/>
16	BAYNHAM, S.A., et al., "Treating stage IV pressure ulcers with negative pressure therapy: a case report", Ostomy Wound Manage., 45(4):28-32, 34-35 (April 1999). NPL-041	<input type="checkbox"/>
17	BERTONE, A.L., et al., "Management of Exuberant Granulation Tissue", Veterinary Clinic of North America – Equine Practice, 5(3):551-562 (December 1989). NPL-043	<input type="checkbox"/>
18	BIRCHALL, L., et al., "Developing a trust-wide centralised approach to the use of TNP", J. Wound Care, 11(8):311-4 (September 2002). NPL-047	<input type="checkbox"/>
19	BlueSky Medical "The Versatile One™", Wound Drainage and More, 1 page advertisement (labeled Spring 2003). NPL-050	<input type="checkbox"/>
20	BlueSky Medical Support, printout of webpage www.woundvacuum.com/Standard%20pp/support.htm, pp 1-3 (October 11, 2005). NPL-051	<input type="checkbox"/>
21	BlueSky Medical, "A Leader in Suction Technology – Wound Drainage Experts", printout of entire website, 55 pp., www.blueskymedical.com (April 8, 2003). NPL-052	<input type="checkbox"/>
22	BlueSky Medical, Negative Pressure Wound Therapy, Product Catalog, "Finally a choice..." 8 pp. (Fall 2005). NPL-053	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

23	BONNAMY, C., et al., "Use of the vacuum-assisted closure system for the treatment of perineal gangrene involving the abdominal wall", Ann. Chir., (English abstract on first page and 1 sheet PubMed abstract) 125(10):982-4 (December 2000). NPL-054	<input type="checkbox"/>
24	BORZOV, M.V., et al., "Vacuum therapy of some skin diseases", Vestn. Dermatol. Venerol., (English abstract on last page, 10 pp. of English translation, and one sheet from PubMed) 39(8):50-56 (August 1965). NPL-055	<input type="checkbox"/>
25	BRODY, G.S., "Biological creep", Plast. Reconstr. Surg., 92(6):1202-1203 (November 1993). NPL-060	<input type="checkbox"/>
26	BYERS, R.M., "Clinical effects of closed suction drainage on wound healing in patients with head and neck cancer", Arch. Otolaryngol., 108:723-6 (November 1982). NPL-066	<input type="checkbox"/>
27	CAMBELL, Penny; Promotional Slide Presentation 27 pp., (dated Oct. 14, 2005). NPL-067	<input type="checkbox"/>
28	CAMPION-JOHNSTON, S., et al., "Infected wound management: advanced technologies, moisture-retentive dressings, and die-hard methods", Crit. Care Nurs. Q., 24(2):64-77 (August 2001). NPL-068	<input type="checkbox"/>
29	CARROLL, P., "The principles of vacuum and its use in the hospital environment", 2nd ed., Ohmeda, 31 sheets. NPL-070	<input type="checkbox"/>
30	CESANY, P., "Suction in the treatment of torpid ulcerations", Rozhl. Chir., (English abstract on page 409 (5 sheets) and 1 sheet printout from PubMed) 48(9):406-409 (September 1969). NPL-072	<input type="checkbox"/>
31	CHARIKER, M. E. et al. (eds), "Effective management of incisional and cutaneous fistulae with closed suction wound drainage", Contemporary Surg., 34:59-63 (June 1989). NPL-073	<input type="checkbox"/>
32	Chariker-Jeter Status Link from the website www.trademark.com/cbi-bin/tmlist, 1 page (October 14, 2005). NPL-074	<input type="checkbox"/>
33	Chariker-Jeter Technique Tutorial by Penny E. Campbell, Wound Care Solutions. NPL-075	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

34	CHEN, K.D., et al., "Mechanotransduction in response to shear stress", <i>J. Biol. Chem.</i> , 274(26):18393-18400, (June 25, 1999). NPL-081	<input type="checkbox"/>
35	CHINN, S.D., "Closed wound suction drainage", <i>J. Foot Surg.</i> , 24(1):76-81 (January-February 1985). NPL-083	<input type="checkbox"/>
36	CLARE, M.P., et al., "Experience with the vacuum assisted closure negative pressure technique in the treatment of non-healing diabetic and dysvascular wounds", <i>Foot Ankle Int.</i> , 23(10):896-901 (October 2002). NPL-084	<input type="checkbox"/>
37	CLAXTON, M.J., et al., "Healing the diabetic wound and keeping it healed: modalities for the early 21st century", <i>Curr. Diab. Rep.</i> , 2(6):510-8 (December 2002). NPL-086	<input type="checkbox"/>
38	COGGRAVE, M., et al., "Topical negative pressure for pressure ulcer management", <i>Br. J. Nurs.</i> , 11(6 Suppl):S29-31, S33-34, S36 (March 2002). NPL-089	<input type="checkbox"/>
39	COLLIER, M., "Know how: Vacuum assisted closure (VAC)", <i>Nurs. Times</i> , 93(5):32-3 (January 29-February 4 1997). NPL-090	<input type="checkbox"/>
40	COOPER, S.M., et al., "Topical negative pressure", <i>Int. J. Dermatol.</i> , 39(12):896-8 (December 2000). NPL-098	<input type="checkbox"/>
41	COZART, R.F., et al., "The use of controlled subatmospheric pressure to promote wound healing in preparation for split-thickness skin grafting in a fourth degree burn", <i>Tenn. Med.</i> , 92(10):382-4 (October 1999). NPL-103	<input type="checkbox"/>
42	CRO, C., et al., "Vacuum assisted closure system in the management of enterocutaneous fistulae," <i>Postgrad. Med. J.</i> , 78(925):364-5 (November 2002). NPL-104	<input type="checkbox"/>
43	DE FILIPPO, R.E., et al., "Stretch and growth: the molecular and physiologic influences of tissue expansion", <i>Plast. Reconstr. Surg.</i> , 109(7):2450-2462 (June 2002). NPL-110	<input type="checkbox"/>
44	DEVA, A.K., et al., "Vacuum-assisted closure of a sacral pressure sore", <i>J. Wound Care</i> , 6(7) 311-312, (July 1997). NPL-114	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

45	DUNFORD, C., "Hypergranulation tissue", J. Wound Care, 8(10):506-507 (November 1999). NPL-123	<input type="checkbox"/>
46	DUNFORD, C.E., "Treatment of a wound infection in a patient with mantle cell lymphoma", Br. J. Nurs., 10(16):1058, 1060, 1062, 1064-5 (September 13-26, 2001). NPL-124	<input type="checkbox"/>
47	Email dated January 14, 2002 with attachments, including "Report of Meeting with DG Consulting", 5 sheets, (Exhibit D-157) (dated January 10, 2002). NPL-137	<input type="checkbox"/>
48	ESPENSEN, E.H., et al., "Use of subatmospheric (VAC) therapy to improve bioengineered tissue grafting in diabetic foot wounds", J. Am. Podiatr. Med. Assoc., 92(7):395-7 (July - August 2002). NPL-142	<input type="checkbox"/>
49	WESTABY, S., "Treatment of purulent wounds and fistulae with an adhesive wound irrigation device", Ann. R. Coll. Surg., 63(5):353-6 (September 1981). NPL-145	<input type="checkbox"/>
50	FLECK, T.M., et al., "The vacuum-assisted closure system for the treatment of deep sternal wound infections after cardiac surgery", Ann. Thorac. Surg., 74(5):1596-600 (November 2002). NPL-155	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.
 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Niels Haun/	Date (YYYY-MM-DD)	2007-04-30
Name/Print	Niels Haun	Registration Number	48,488

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 216(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.